Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx2 HAV
- Development stage
- Phase 1
- Lead developer
- HAV Vaccines
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx2 HAV is a recombinant viral vector vaccine candidate developed to target Mycobacterium avium subspecies paratuberculosis (MAP), a bacterium implicated in the pathogenesis of Crohn’s disease. The vaccine uses the ChAdOx2 platform, which is a simian adenovirus vector engineered to express antigens from MAP. Its mechanism involves inducing an immune response against MAP, potentially reducing bacterial load and improving clinical outcomes in Crohn’s disease patients. The vaccine has been evaluated both as a single agent and as part of a heterologous prime-boost regimen with MVA HAV (Modified Vaccinia Ankara expressing MAP antigens). Clinical trials have focused on assessing safety, tolerability, and immunogenicity in healthy volunteers and patients with active Crohn's disease[1][2][3][4].
- Other names
- ChAdOx2-HAVChAdOx-2-HAVChAdOx 2-HAV
Beyond the preview
Go deeper on ChAdOx2 HAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx2 HAV.